Single-cell analysis of CLL cells from 6 subjects
| Gene . | Total cells analyzed, n . | Cells PCR positive, n . | Cells sequenced, n . | Shared, n* . | Partially shared, n† . | Unique, n‡ . |
|---|---|---|---|---|---|---|
| Patient 012 | ||||||
| VH4-59§ | 160 | 108 | 43 | 16 | 6 | 4 |
| Vk1 (L12)§ | 160 | 109 | 43 | 19 | 4 | 5 |
| β-Globin | 160 | 144 | 43 | 0 | 0 | 1 |
| Patient 038 | ||||||
| VH5-51§ | 40 | 25 | 21 | 9 | 0 | 0 |
| VL8a§ | 40 | 32 | 21 | 5 | 0 | 1 |
| β-Globin | 50 | 40 | 0 | — | — | — |
| Patient 011‖ | ||||||
| VH3-74§ | 10 | 7 | 7 | 20 | 0 | 0 |
| β-Globin | 80 | 10 | 0 | — | — | — |
| Patient 052 | ||||||
| VH3-11§ | 40 | 35 | 29 | 14 | 0 | 3 |
| Vk3 (L2)§ | 40 | 34 | 29 | 8 | 0 | 0 |
| VL8a | 40 | 22 | 15 | 5 | 0 | 7 |
| β-Globin | 40 | 35 | 0 | — | — | — |
| Patient 043 | ||||||
| VH2-05§ | 40 | 25 | 23 | 14 | 0 | 1 |
| VH6-01# | 40 | 23 | 22 | 25 | 0 | 2 |
| Vk2 (A18)¶# | 40 | 29 | 24 | 1 | 0 | 4 |
| VL3m§ | 40 | 28 | 25 | 11 | 0 | 4 |
| VL4b§# | 40 | 37 | 31 | 26 | 0 | 1 |
| β-Globin | 40 | 40 | 0 | — | — | — |
| Patient 151 | ||||||
| VH3-23§ | 280 | 67 | 47 | 9 | 5 | 0 |
| Vk2 (A19)§ | 280 | 85 | 47 | 2 | 2 | 2 |
| VL8a§# | 280 | 107 | 27 | 6 | 1 | 7 |
| β-Globin | 280 | 143 | 47 | 0 | 0 | 1 |
| Gene . | Total cells analyzed, n . | Cells PCR positive, n . | Cells sequenced, n . | Shared, n* . | Partially shared, n† . | Unique, n‡ . |
|---|---|---|---|---|---|---|
| Patient 012 | ||||||
| VH4-59§ | 160 | 108 | 43 | 16 | 6 | 4 |
| Vk1 (L12)§ | 160 | 109 | 43 | 19 | 4 | 5 |
| β-Globin | 160 | 144 | 43 | 0 | 0 | 1 |
| Patient 038 | ||||||
| VH5-51§ | 40 | 25 | 21 | 9 | 0 | 0 |
| VL8a§ | 40 | 32 | 21 | 5 | 0 | 1 |
| β-Globin | 50 | 40 | 0 | — | — | — |
| Patient 011‖ | ||||||
| VH3-74§ | 10 | 7 | 7 | 20 | 0 | 0 |
| β-Globin | 80 | 10 | 0 | — | — | — |
| Patient 052 | ||||||
| VH3-11§ | 40 | 35 | 29 | 14 | 0 | 3 |
| Vk3 (L2)§ | 40 | 34 | 29 | 8 | 0 | 0 |
| VL8a | 40 | 22 | 15 | 5 | 0 | 7 |
| β-Globin | 40 | 35 | 0 | — | — | — |
| Patient 043 | ||||||
| VH2-05§ | 40 | 25 | 23 | 14 | 0 | 1 |
| VH6-01# | 40 | 23 | 22 | 25 | 0 | 2 |
| Vk2 (A18)¶# | 40 | 29 | 24 | 1 | 0 | 4 |
| VL3m§ | 40 | 28 | 25 | 11 | 0 | 4 |
| VL4b§# | 40 | 37 | 31 | 26 | 0 | 1 |
| β-Globin | 40 | 40 | 0 | — | — | — |
| Patient 151 | ||||||
| VH3-23§ | 280 | 67 | 47 | 9 | 5 | 0 |
| Vk2 (A19)§ | 280 | 85 | 47 | 2 | 2 | 2 |
| VL8a§# | 280 | 107 | 27 | 6 | 1 | 7 |
| β-Globin | 280 | 143 | 47 | 0 | 0 | 1 |
— indicates not determined.
Mutations present in all sequences from a given subject.
Mutations present in more than one but not all sequences from a given subject.
Mutations present in only one sequence from a given subject.
Immunoglobulin sequences were also detected as RNA in CLL cells from respective subjects.
Rearranged immunoglobulin light chains were not detected in this subject at the single-cell or 1000-cell level.
Analysis of CLL-cell RNA from this subject identified a productively rearranged and expressed Vk2 (A19) transcript.
All other immunoglobulin genes from all 6 subjects with CLL were productively rearranged except these immunoglobulin genes VH6-01, Vk2 (A18), VL4b and VL8a, which were nonproductive.